Cubist Pharmaceuticals, Inc. (CBST)

[surf1944]

4:04PM Cubist Pharma misses by $0.03, reports revs in-line (CBST) 20.57 -0.32 : Reports Q4 (Dec) earnings of $0.38 per share, $0.03 worse than the First Call consensus of $0.41; revenues rose 27.1% year/year to $166.7 mln vs the $165.6 mln consensus. CBST reports Cubicin drug sales of $147.8 mln vs. $129.6 mln First Call Consensus. "As we begin 2010, Cubist continues to build on the foundation we've created with the development and commercial success of CUBICIN. Our acute care focus and our disciplined approach to building a pipeline of differentiated therapies addressing areas of high unmet medical need puts Cubist in a strong position during times of continued uncertainty in the economy overall and in the healthcare marketplace in particular."